NASDAQ:GUTS

Fractyl Health (GUTS) Stock Price, News & Analysis

$7.15
+0.53 (+8.01%)
(As of 04:00 PM ET)
Today's Range
$6.49
$7.17
50-Day Range
$6.06
$9.10
52-Week Range
$5.75
$14.50
Volume
194,255 shs
Average Volume
319,594 shs
Market Capitalization
$342.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
GUTS stock logo

About Fractyl Health Stock (NASDAQ:GUTS)

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

GUTS Stock Price History

GUTS Stock News Headlines

Fractyl Health (GUTS) Set to Announce Earnings on Monday
See More Headlines
Receive GUTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fractyl Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2024
Today
5/15/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:GUTS
Previous Symbol
NASDAQ:GUTS
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$26.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+209.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$120,000.00

Miscellaneous

Free Float
N/A
Market Cap
$339.95 million
Optionable
N/A
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Harith Rajagopalan M.D. (Age 47)
    Ph.D., Co-Founder, CEO & Director
    Comp: $863.77k
  • Mr. Jay D. Caplan BSEE (Age 62)
    MBA, Co-Founder, Chief Product Officer & President
    Comp: $555.19k
  • Dr. Timothy J. Kieffer Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $140.64k
  • Ms. Lisa A. Davidson MBA (Age 57)
    CFO & Treasurer
  • Ms. Sarah S. Toomey Esq. (Age 49)
    General Counsel & Corporate Secretary
    Comp: $479.36k
  • Dr. Helmut Giersiefen
    Head of Business Development
  • Mr. Adrian Kimber
    Chief Commercial Officer

GUTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Fractyl Health stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fractyl Health in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GUTS shares.
View GUTS analyst ratings
or view top-rated stocks.

What is Fractyl Health's stock price target for 2024?

3 equities research analysts have issued 1-year price targets for Fractyl Health's shares. Their GUTS share price targets range from $18.00 to $26.00. On average, they expect the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 209.9% from the stock's current price.
View analysts price targets for GUTS
or view top-rated stocks among Wall Street analysts.

How have GUTS shares performed in 2024?

Fractyl Health's stock was trading at $12.85 on January 1st, 2024. Since then, GUTS stock has decreased by 44.7% and is now trading at $7.10.
View the best growth stocks for 2024 here
.

When is Fractyl Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our GUTS earnings forecast
.

How were Fractyl Health's earnings last quarter?

Fractyl Health, Inc. (NASDAQ:GUTS) posted its quarterly earnings data on Monday, April, 1st. The company reported ($8.02) earnings per share (EPS) for the quarter. The business earned $0.01 million during the quarter.

When did Fractyl Health IPO?

Fractyl Health (GUTS) raised $110 million in an initial public offering (IPO) on Friday, February 2nd 2024. The company issued 7,333,333 shares at a price of $15.00 per share.

When does Fractyl Health's lock-up period expire?

Fractyl Health's lock-up period expires on Wednesday, July 31st. Fractyl Health had issued 7,333,333 shares in its initial public offering on February 2nd. The total size of the offering was $109,999,995 based on an initial share price of $15.00. After the end of Fractyl Health's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Fractyl Health's major shareholders?

Fractyl Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include M28 Capital Management LP (3.88%) and American International Group Inc. (2.80%).
View institutional ownership trends
.

How do I buy shares of Fractyl Health?

Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GUTS) was last updated on 5/15/2024 by MarketBeat.com Staff

From Our Partners